Crispr Therapeutics (NASDAQ:CRSP) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report sent to investors on Thursday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $64.00 price target on the stock.

A number of other equities research analysts have also weighed in on CRSP. Barclays boosted their target price on Crispr Therapeutics from $59.00 to $62.00 and gave the company an overweight rating in a research note on Tuesday. William Blair reissued a hold rating on shares of Crispr Therapeutics in a research note on Tuesday. Roth Capital boosted their target price on Crispr Therapeutics from $50.00 to $65.00 in a research note on Tuesday. Chardan Capital set a $73.00 target price on Crispr Therapeutics and gave the company a buy rating in a research note on Friday, June 7th. Finally, BidaskClub raised Crispr Therapeutics from a sell rating to a hold rating in a research note on Tuesday, April 30th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $58.00.

Shares of NASDAQ CRSP traded down $2.67 during midday trading on Thursday, reaching $49.89. The company had a trading volume of 563,445 shares, compared to its average volume of 658,606. Crispr Therapeutics has a one year low of $22.22 and a one year high of $59.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.84 and a current ratio of 13.96. The company’s fifty day simple moving average is $47.92. The company has a market cap of $2.77 billion, a PE ratio of -14.50 and a beta of 3.11.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, July 29th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.84). Crispr Therapeutics had a negative net margin of 15,136.56% and a negative return on equity of 51.49%. The company had revenue of $0.32 million during the quarter, compared to the consensus estimate of $47.57 million. During the same period last year, the firm posted ($0.82) EPS. The company’s revenue was down 70.8% on a year-over-year basis. As a group, research analysts anticipate that Crispr Therapeutics will post -3.86 earnings per share for the current fiscal year.

In other Crispr Therapeutics news, President Rodger Novak sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $50.00, for a total transaction of $2,500,000.00. Following the completion of the transaction, the president now owns 848,007 shares of the company’s stock, valued at approximately $42,400,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Lawrence Otto Klein sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $50.02, for a total value of $1,000,400.00. Following the transaction, the insider now directly owns 31,579 shares of the company’s stock, valued at approximately $1,579,581.58. The disclosure for this sale can be found here. Insiders have sold a total of 140,000 shares of company stock valued at $6,670,400 in the last ninety days. 21.40% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Valeo Financial Advisors LLC raised its position in Crispr Therapeutics by 71.4% during the 1st quarter. Valeo Financial Advisors LLC now owns 725 shares of the company’s stock valued at $26,000 after purchasing an additional 302 shares during the last quarter. Flagship Harbor Advisors LLC raised its position in Crispr Therapeutics by 22.1% during the 1st quarter. Flagship Harbor Advisors LLC now owns 3,309 shares of the company’s stock valued at $118,000 after purchasing an additional 600 shares during the last quarter. Creative Planning raised its position in Crispr Therapeutics by 4.7% during the 1st quarter. Creative Planning now owns 15,486 shares of the company’s stock valued at $553,000 after purchasing an additional 695 shares during the last quarter. BNP Paribas Arbitrage SA purchased a new position in shares of Crispr Therapeutics during the 2nd quarter worth approximately $41,000. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Crispr Therapeutics by 5.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock worth $839,000 after acquiring an additional 986 shares during the period. 48.92% of the stock is owned by institutional investors and hedge funds.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: What are economic reports?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.